Orexo AB (publ) (LON:0H19)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 71.28M +64.5% |
| Revenue (ttm) | 2.10M -95.6% |
| Net Income | 51.53M |
| EPS | 1.49 |
| Shares Out | n/a |
| PE Ratio | 1.38 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 1,238 |
| Open | n/a |
| Previous Close | 26.40 |
| Day's Range | n/a |
| 52-Week Range | 12.90 - 41.20 |
| Beta | 0.83 |
| RSI | 35.48 |
| Earnings Date | Mar 27, 2026 |
About Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ... [Read more]
News
Invitation & Agenda: Orexo R&D Day on March 24
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026.
Orexo changes the organizational structure and management team to increase focus on development of new products
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team.
Orexo AB (ORXOF) Q4 2025 Earnings Call Highlights: Strategic Divestment and Financial Resilience
Orexo AB (ORXOF) Q4 2025 Earnings Call Highlights: Strategic Divestment and Financial Resilience
Q4 2025 Orexo AB Earnings Call Transcript
Q4 2025 Orexo AB Earnings Call Transcript
Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript
Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript
Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript
Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript
Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript
Orexo AB (publ) (OTCQX:ORXOY) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Nikolaj Sørensen - President & CEO Frederik Jarrsten - Executive VP & CFO Edward Kim Conference Ca...
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared wi...
Orexo to present clinical data for OX640 at the EAACI Congress
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technology EAACI is a ...
Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields. Both formulations te...
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vacci...
Orexo initiates new study of OX640 in participants with allergic rhinitis
OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.
Orexo´s Nomination Committee for the Annual General Meeting 2025
UPPSALA, Sweden , Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises of the f...
Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
UPPSALA, Sweden , Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food and Drug Ad...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world´s most trusted provi...
Orexo: invitation to presentation of the Q2 2024 Interim Report
UPPSALA, Sweden , July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm, analysts, ...
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
UPPSALA, Sweden , May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating rate social...
Report from Orexo AB's annual general meeting, 26 April 2024
UPPSALA, Sweden, April 26, 2024 /PRNewswire/ -- Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance with the nominatio...
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
UPPSALA, Sweden , April 17, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent sp...
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
UPPSALA, Sweden, April 2, 2024 /PRNewswire/ -- On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's e...
Orexo publishes the Annual and Sustainability Report for 2023
UPPSALA, Sweden , March 28, 2024 /PRNewswire/ -- Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com . The Swedish version of the Report is als...
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
UPPSALA, Sweden , March 13, 2024 /PRNewswire/ -- Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued new senior secured callable floating rate social bonds in a...
Orexo strengthens its sustainability work by establishing a social financing framework
UPPSALA, Sweden , March 8, 2024 /PRNewswire/ -- Orexo AB (publ), ('Orexo' or the 'Company') (STO: ORX) (OTCQX: ORXOY) today announces that the Company has established a social financing framework date...